

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Austedo 12 mg prolonged-release tablets
Austedo 24 mg prolonged-release tablets
Austedo 30 mg prolonged-release tablets
Austedo 36 mg prolonged-release tablets
Austedo 42 mg prolonged-release tablets
Austedo 48 mg prolonged-release tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Austedo 12 mg prolonged-release tablets

Each prolonged-release tablet contains 12 mg of deutetetrabenazine.
Excipient with known effect
Each prolonged-release tablet contains 0.32 mg of allura red AC.

Austedo 24 mg prolonged-release tablets

Each prolonged-release tablet contains 24 mg of deutetetrabenazine.
Excipient with known effect
Each prolonged-release tablet contains 0.94 mg of allura red AC.

Austedo 30 mg prolonged-release tablets

Each prolonged-release tablet contains 30 mg of deutetetrabenazine.
Excipients with known effect
Each prolonged-release tablet contains 0.45 mg of allura red AC and 0.14 mg of sunset yellow FCF.

Austedo 36 mg prolonged-release tablets

Each prolonged-release tablet contains 36 mg of deutetetrabenazine.
Excipients with known effect
Each prolonged-release tablet contains 0.70 mg of allura red AC and 0.03 mg of sunset yellow FCF.

Austedo 42 mg prolonged-release tablets

Each prolonged-release tablet contains 42 mg of deutetetrabenazine.
Excipients with known effect
Each prolonged-release tablet contains 1.21 mg of allura red AC and 1.17 mg of sunset yellow FCF.

Austedo 48 mg prolonged-release tablets

Each prolonged-release tablet contains 48 mg of deutetetrabenazine.
Excipient with known effect
Each prolonged-release tablet contains 0.83 mg of allura red AC.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Prolonged-release tablet

Austedo 12 mg prolonged-release tablets

The tablets are round, blue, film-coated, with a diameter of approximately 9 mm and “Q12” printed in black ink on one side.

Austedo 24 mg prolonged-release tablets

The tablets are round, purple, film-coated, with a diameter of approximately 9 mm and “Q24” printed in black ink on one side.

Austedo 30 mg prolonged-release tablets

The tablets are round, light orange, film-coated, with a diameter of approximately 10 mm and “Q30” printed in black ink on one side.

Austedo 36 mg prolonged-release tablets

The tablets are round, light purple, film-coated, with a diameter of approximately 10 mm and “Q36” printed in black ink on one side.

Austedo 42 mg prolonged-release tablets

The tablets are round, orange, film-coated, with a diameter of approximately 10 mm and “Q42” printed in black ink on one side.

Austedo 48 mg prolonged-release tablets

The tablets are round, pink, film-coated, with a diameter of approximately 10 mm and “Q48” printed in black ink on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Austedo is indicated for the treatment of moderate to severe tardive dyskinesia in adults.

4.2 Posology and method of administration

The initiation and titration of Austedo treatment should be supervised by a physician with experience in drug-induced movement disorders.

Posology

Austedo dosing should be determined individually for each patient, based on adequate reduction of tardive dyskinesia symptoms and tolerability.

Therapy should be initiated at 12 mg once daily for one week. The dose should then be increased to 24 mg once daily for another week. After the second week, it is recommended that the dose be titrated at weekly intervals in increments of 6 mg once daily, based on reduction of tardive dyskinesia symptoms and tolerability. The efficacious dose range is considered to be 24 mg to 48 mg. The maximum recommended daily dose is 48 mg.

In patients receiving strong CYP2D6 inhibitors or who are poor CYP2D6 metabolisers, the daily dose of deutetrabenazine should not exceed 36 mg (see sections 4.5 and 5.2).

A decision to continue treatment with deutetrabenazine should be taken on an individual patient basis. Treatment can be continued for as long as a therapeutic benefit is observed, and the patient tolerates treatment.

Treatment with deutetrabenazine can be discontinued without the need for tapering off.

Missed doses

If a patient misses doses for less than one week, treatment can be resumed at the current dose. If the patient misses doses for more than one week, Austedo therapy should be restarted at 12 mg once daily.

Special populations

Elderly

There is limited data available on the use of deutetrabenazine in patients ≥ 65 years of age. Based on the results of population pharmacokinetic analysis, no dose adjustment is required (see section 5.2).

Hepatic impairment

The use of deutetrabenazine in patients with hepatic impairment is contraindicated (see sections 4.3 and 5.2).

Renal impairment

No dose adjustment is necessary in patients with renal impairment (see section 5.2).

Paediatric population

There is no relevant use of Austedo in the paediatric population for the indication of tardive dyskinesia.

Method of administration

For oral use.

The prolonged-release tablets can be taken with or without food. To preserve the prolonged-release properties, the tablets must be swallowed whole with water, not chewed, crushed or divided.

The active substance is contained within a non-absorbable shell designed to release the active substance at a controlled rate. The tablet shell is eliminated from the body. Patients should be advised that they may occasionally notice in their stool something that looks like a tablet.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hepatic impairment (see section 4.2).

Concomitant treatment with reserpine (see section 4.5).

Concomitant treatment with monoamine oxidase inhibitors (MAOIs) (see section 4.5).

Concomitant treatment with other vesicular monoamine transporter 2 (VMAT2) inhibitors (see section 4.5).

4.4 Special warnings and precautions for use

Depression

Deutetrabenazine may cause depression or worsen pre-existing depression (see section 4.8). Patients should be closely monitored for the emergence of such adverse reactions. Patients and their caregivers should be informed of the risks and instructed to report any concerns to their doctor immediately. If depression does not resolve, discontinuing treatment with deutetrabenazine should be considered.

QTc prolongation

Deutetrabenazine may prolong the QTc interval, but the degree of QTc prolongation is not clinically significant when deutetrabenazine is administered within the recommended dose range (see section 5.1). Deutetrabenazine should be used with caution in combination with other medicinal products that prolong the QTc interval (see section 4.5) and in patients with congenital long QT syndrome, bradycardia, hypokalaemia, hypomagnesaemia or a history of cardiac arrhythmias.

Neuroleptic malignant syndrome (NMS)

There is a potential risk of NMS associated with medicinal products that reduce dopaminergic transmission (see section 4.5). Main symptoms of NMS are mental changes, rigidity, hyperthermia, autonomic dysfunction and elevated creatinine phosphokinase levels. If NMS is suspected, deutetrabenazine should be discontinued immediately and appropriate symptomatic treatment should be initiated.

Akathisia, agitation and restlessness

Deutetrabenazine may increase the risk of akathisia, agitation, and restlessness in patients with tardive dyskinesia (see section 4.8). Patients receiving deutetrabenazine should be monitored for signs and symptoms of restlessness and agitation, as these may be indicators of developing akathisia. If a patient develops akathisia during treatment with deutetrabenazine, the dose should be reduced; some patients may require discontinuation of therapy.

Somnolence

Somnolence is a very common dose-limiting adverse reaction of deutetrabenazine (see section 4.8) and, therefore, patients should be advised to exercise caution when driving or operating machines (see section 4.7). Due to possible additive effects, caution should also be advised when patients are taking other sedating products or alcohol in combination with deutetrabenazine (see section 4.5).

Parkinsonism

Deutetrabenazine may cause parkinsonism in patients with tardive dyskinesia (see section 4.8). If a patient develops parkinsonism, the deutetrabenazine dose should be reduced and discontinuation of treatment should be considered if the event does not resolve.

Binding to melanin-containing tissues

Since deutetrabenazine or its metabolites bind to melanin-containing tissues (e.g. skin and eye), it could accumulate in these tissues over time. This raises the possibility that deutetrabenazine may cause toxicity in these tissues after extended use. The clinical relevance of deutetrabenazine's binding to melanin-containing tissues is unknown.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per prolonged-release tablet, i.e. is essentially 'sodium-free'.

This medicinal product contains sunset yellow FCF and/or allura red AC which may cause allergic reactions (see section 2).

4.5 Interaction with other medicinal products and other forms of interaction

Reserpine

Deutetrabenazine and reserpine must not be used concomitantly (see section 4.3). Reserpine binds irreversibly to VMAT2 and the duration of its effect is several days. At least 20 days must elapse after stopping reserpine before starting deutetrabenazine. Prescribers should wait for dyskinesia to re-emerge before administering deutetrabenazine to help reduce the risk of overdose and major depletion of serotonin and noradrenaline in the central nervous system.

Monoamine Oxidase Inhibitors (MAOIs)

Deutetrabenazine must not be used in combination with an MAOI (e.g. moclobemide, tranylcypromine, isocarboxazid, selegiline, rasagiline, safinamide, linezolid) (see section 4.3). At least 14 days must elapse after stopping an MAOI before starting deutetrabenazine.

Other VMAT2 inhibitors

Deutetrabenazine must not be used in patients currently taking other VMAT2 inhibitors (e.g. tetrabenazine) (see section 4.3). Deutetrabenazine can be started the day after the discontinuation of tetrabenazine at a dose which is approximately half the tetrabenazine daily dose.

Medicinal products known to reduce dopaminergic transmission

The risk of parkinsonism, NMS, and akathisia may be increased by concomitant use of medicinal products that reduce dopaminergic transmission (e.g. haloperidol, chlorpromazine, metoclopramide, ziprasidone, promazine), therefore caution is recommended (see section 4.4).

Medicinal products known to prolong the QTc interval

Deutetrabenazine may prolong the QTc interval. Deutetrabenazine should be used with caution in combination with other medicinal products that prolong the QTc interval (see section 4.4). Examples of medicinal products that prolong the QTc interval include: antiarrhythmics class IA (e.g. quinidine, disopyramide) and class III (e.g. amiodarone, sotalol), antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol, droperidol, ziprasidone), tricyclic antidepressants (e.g. amitriptyline), selective serotonin reuptake inhibitors (e.g. citalopram, escitalopram), antimicrobials (e.g. fluoroquinolones, triazole derivative (e.g. voriconazole), erythromycin IV, pentamidine, antimalarial medicinal products), and antihistamines (e.g. hydroxyzine, mizolastine).

Alcohol or other sedating products

Concomitant use of alcohol or other sedating products is not recommended, as these may have additive effects and worsen sedation and somnolence (see section 4.4). Examples of sedating products include benzodiazepines (e.g. midazolam, diazepam, lorazepam), antidepressants (e.g. mirtazapine, amitriptyline, trazodone), antipsychotics (e.g. promethazine, chlorprothixene), opioids (e.g. oxycodone, buprenorphine), antihistamines (e.g. diphenhydramine, dimenhydrinate), and centrally acting antihypertensives (e.g. clonidine, moxonidine).

Strong CYP2D6 inhibitors

Concomitant use of strong CYP2D6 inhibitors, such as quinidine (antiarrhythmic and antimalarial medicinal product), and paroxetine, fluoxetine, and bupropion (antidepressants), has been shown to increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine. In the presence of a strong CYP2D6 inhibitor (paroxetine), systemic exposure of the individual active metabolites increased 1.9-fold for deuterated α -dihydrotetrabenazine [HTBZ] and 6.5-fold for deuterated β -HTBZ resulting in an overall 3-fold increase in the active metabolites, deuterated total ($\alpha + \beta$)-HTBZ (see section 5.2). A reduction in the dose of deutetrabenazine may be necessary when adding a strong

CYP2D6 inhibitor in patients maintained on a stable dose of deutetrabenazine. The daily dose of deutetrabenazine should not exceed 36 mg in patients taking strong CYP2D6 inhibitors (see section 4.2).

Levodopa and other dopaminergic medicinal products

Levodopa and other dopaminergic medicinal products (e.g. pramipexole, ropinirole) may reduce the effect of deutetrabenazine. Caution should be applied if deutetrabenazine is used with levodopa and other dopaminergic medicinal products.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is a limited amount of data from the use of deutetrabenazine in pregnant women.

Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).

Austedo is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether deutetrabenazine or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Austedo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

The effect of deutetrabenazine on fertility in humans and animals has not been evaluated. Oral administration of deutetrabenazine to female rats resulted in oestrous cycle disruption (see section 5.3). In animal studies with tetrabenazine, female cycle lengths were increased and a delay in fertility was observed.

4.7 Effects on ability to drive and use machines

Deutetrabenazine has moderate influence on the ability to drive and use machines. Deutetrabenazine may cause somnolence, therefore patients being treated with deutetrabenazine should be advised to refrain from driving or operating hazardous machinery, until they are on a maintenance dose and know how the medicinal product affects them (see section 4.4).

4.8 Undesirable effects

Summary of the safety profile

Most commonly reported adverse reactions associated with deutetrabenazine were somnolence (11%), diarrhoea, dry mouth, and fatigue (each 9%). Somnolence may occur more frequently at the beginning of treatment and decrease with treatment continuation.

The most serious adverse reactions were depression and dysthymic disorder (2%).

Tabulated list of adverse reactions

Adverse reactions from clinical studies and post-marketing reports are presented according to MedDRA system organ classification. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Frequency categories are based on the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1\,000$ to $< 1/100$), rare ($\geq 1/10\,000$ to $< 1/1\,000$) and not known (cannot be estimated from the available data).

The following adverse reactions have been identified for deutetrabenazine (see Table 1).

Table 1: List of adverse reactions

System Organ Class	Frequency	Adverse Reaction
Infections and infestations	Common	Urinary tract infection
		Nasopharyngitis
Psychiatric disorders	Common	Depression*
		Dysthymic disorder*
		Anxiety
		Insomnia
		Agitation**
		Restlessness**
Nervous system disorders	Very common	Somnolence
	Common	Akathisia**
	Uncommon	Parkinsonism
Gastrointestinal disorders	Common	Diarrhoea
		Constipation
		Dry mouth
General disorders and administration site conditions	Common	Fatigue
Injury, poisoning and procedural complications	Common	Contusion

* Preferred terms depression and dysthymic disorder were grouped for frequency calculation.

** Preferred terms agitation, restlessness and akathisia were grouped for frequency calculation.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

4.9 Overdose

Experience with doses higher than the recommended maximum daily dose of 48 mg is limited. Isolated cases of deutetrabenazine overdose (up to 240 mg per day) have been derived from post-marketing reports and literature. The most frequently observed symptoms were: somnolence, increase in movements, fatigue, agitation and restlessness, insomnia, and suicidal ideation. One additional case reported in the literature included a patient taking 720 mg who experienced toxic encephalopathy, dyskinesia, and psychomotor hyperactivity.

In case of symptoms suggestive for overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse events and given appropriate symptomatic treatment if necessary. The possible involvement of multiple medicinal products should always be considered. No specific antidote is known. Forced diuresis and dialysis are unlikely to be of benefit.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other nervous system drugs, ATC code: N07XX16.

Mechanism of action

Deutetrabenazine and the major circulating metabolites (deuterated α -HTBZ and deuterated β -HTBZ), are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic

vesicles and depletion of monoamine stores in dopaminergic regions (e.g. striatum and cortex) of the brain (see section 5.2 “Distribution”). While the precise mechanism of action by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia is unknown, it is believed to be related to its effect as a depleter of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals.

Pharmacodynamic effects

Cardiac electrophysiology

At the maximum recommended dose, deutetrabenazine does not prolong the QTc interval to any clinically relevant extent. An exposure-response analysis on QTc prolongation from a study conducted in extensive, intermediate and poor CYP2D6 metabolisers, showed that a clinically relevant effect can be excluded at exposures following daily doses of 24 and 48 mg of deutetrabenazine.

Clinical efficacy and safety

The efficacy of deutetrabenazine was assessed in two 12-week, randomised, double-blind, placebo-controlled trials in adult patients with tardive dyskinesia presenting with symptoms that were bothersome to the patient or caused functional impairment (n=335). These studies included patients who had moderate or severe abnormal movements based on Item 8 of the Abnormal Involuntary Movement Scale (AIMS) and a total motor AIMS score of ≥ 6 (based on Items 1 through 7). Enrolled patients had a history of using a dopamine receptor antagonist (DRA, e.g. antipsychotics, metoclopramide) for at least 3 months (or 1 month in patients 60 years of age and older), were psychiatrically stable and had no change in psychoactive medications for at least 30 days (45 days for antidepressants). Background comorbid illnesses included schizophrenia/schizoaffective disorder (n=207, 62%), mood disorder (n=112, 33%), other (neurological, psychiatric and gastrointestinal conditions; n=15, 4%), and missing (n=1, <1%). With respect to concurrent DRA use, 75.5% of the patients were on a stable DRA dose, while 24.5% were not receiving a DRA at baseline. The primary efficacy endpoint in the trials was the total motor AIMS score (the sum of Items 1 to 7 with score range from 0 to 28).

Fixed-dose study (AIM-TD - Study 1)

Study 1 was a 12-week, double-blind, placebo-controlled, fixed-dose trial in adult patients with tardive dyskinesia. A total of 222 patients were randomised into one of four arms: 12 mg deutetrabenazine per day, 24 mg deutetrabenazine per day, 36 mg deutetrabenazine per day, or placebo administered orally. The study included a 4-week dose escalation period and an 8-week maintenance period. The dose of deutetrabenazine was started at 12 mg per day and increased at weekly intervals in 6 mg per day increments to the targeted fixed doses of 12 mg, 24 mg or 36 mg deutetrabenazine per day.

Demographics and baseline disease characteristics were comparable between the study arms. Patients had a mean age of 57 years (range: 21 to 81 years), 24% were 65 years of age and older, 48% were male, and 79% were Caucasian.

Deutetrabenazine showed a statistically significant and clinically meaningful improvement in the AIMS total score from baseline compared to placebo for the 24 mg and 36 mg arms (see Table 2). The effect occurred from as early as week 2 and was sustained over the treatment period (see Figure 1).

Table 2: Improvement in AIMS total score in Study 1


Efficacy endpoint	Placebo (n=58)	Deutetrabenazine 12 mg/day (n=60)	Deutetrabenazine 24 mg/day (n=49)	Deutetrabenazine 36 mg/day (n=55)
AIMS total score				
Mean baseline score (SD)	9.5 (2.71)	9.6 (2.40)	9.4 (2.93)	10.1 (3.21)

LS Mean change from baseline (SE)	-1.4 (0.41)	-2.1 (0.42)	-3.2 (0.45)	-3.3 (0.42)
Treatment effect (95% CI)		-0.7 (-1.84, 0.42)	-1.8 (-3.00, -0.63)	-1.9 (-3.09, -0.79)
p-value				0.001*

LS Mean = Least-squares mean; SD = Standard deviation; SE = Standard error; CI = 2-sided 95% confidence interval

* Multiplicity-adjusted p-value for difference from placebo, statistically significant

Figure 1: Mean change from baseline in AIMS total score in Study 1



Flexible-dose study (ARM-TD - Study 2)

Study 2 was a 12-week, double-blind placebo-controlled, flexible-dose trial in adults with tardive dyskinesia. A total of 113 patients received daily doses of placebo or deutetrabenazine, starting at 12 mg per day with increases allowed at weekly intervals in 6 mg per day increments until adequate dyskinesia control was achieved, a clinically significant adverse reaction occurred, or the maximum daily dose of 48 mg deutetrabenazine per day was reached. The study included a 6-week dose titration period and a 6-week maintenance period. Patients had a mean age of 55 years (range: 25 to 75 years), 14% were 65 years of age and older, 48% were male, and 70% were Caucasian.

The average dose of deutetrabenazine at the end of treatment was 38.3 mg per day. Deutetrabenazine showed a statistically significant and clinically meaningful improvement in the AIMS total score from baseline compared to placebo (see Table 3).

Table 3: Improvement in AIMS total score in Study 2

Efficacy endpoint	Placebo (n=57)	Deutetrabenazine 12 mg/day – 48 mg/day (n=56)
AIMS total score		
Mean baseline score (SD)	9.6 (3.78)	9.7 (4.14)
LS Mean change from baseline (SE)	-1.6 (0.46)	-3.0 (0.45)
Treatment effect (95% CI)		-1.4 (-2.6, -0.2)
p-value		0.0188*

LS Mean = Least-squares mean; SD = Standard deviation; SE = Standard error; CI = 2-sided 95% confidence interval

* Multiplicity-adjusted p value for difference from placebo, statistically significant

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with deutetrabenazine in all subsets of the paediatric population in treatment of tardive dyskinesia (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

After oral dosing deutetrabenazine undergoes rapid and extensive hepatic metabolism to its active metabolites deuterated α -HTBZ and deuterated β -HTBZ resulting in low plasma concentrations of deutetrabenazine compared to that of the active metabolites.

Absorption

Following oral administration of deutetrabenazine, the extent of absorption is at least 80%. Peak plasma concentrations of deutetrabenazine and its active metabolites (deuterated α -HTBZ and deuterated β -HTBZ) are reached within 3 hours after repeated dosing, followed by sustained plateaus for several hours allowing for a 24-hour dosing interval. Absorption is not influenced by food intake.

Distribution

The protein binding of deutetrabenazine, deuterated α -HTBZ and deuterated β -HTBZ in human plasma is 82%, 57%, and 49% respectively, with no preferential binding of total radioactivity to the cellular components of human blood after ^{14}C -deutetrabenazine administration.

Single oral dose of either ^{14}C -deutetrabenazine or ^{14}C -tetrabenazine to rats in a quantitative whole-body autoradiography study resulted in similar blood to brain ratios. Results of PET-scan studies in humans showed that following intravenous injection of ^{11}C -tetrabenazine or α -HTBZ, radioactivity is rapidly distributed to the brain, with the highest binding in the striatum and lowest binding in the cortex. No human PET-scan studies have been performed with deutetrabenazine.

Based on population pharmacokinetic modelling, after oral administration, the apparent volumes of distribution (Vc/F) for deutetrabenazine, deuterated α -HTBZ, and deuterated β -HTBZ is 13 700 L, 490 L, and 860 L, respectively.

Biotransformation

In vitro studies using human liver microsomes demonstrate that deutetrabenazine is extensively biotransformed, mainly by carbonyl reductase, to its major active metabolites, deuterated α -HTBZ and deuterated β -HTBZ, which are subsequently metabolised primarily by CYP2D6, with minor contributions of CYP1A2 and CYP3A4/5, to form several minor metabolites.

Deutetrabenazine and its active metabolites did not inhibit or induce any CYP enzymes that were studied *in vitro* at clinically relevant concentrations.

Elimination

In a mass balance study in six healthy subjects, 75% to 86% of the deutetrabenazine dose was excreted in the urine, and faecal recovery accounted for 8% to 11% of the dose. Urinary excretion of deuterated α -HTBZ and deuterated β -HTBZ each accounted for less than 10% of the administered dose. Sulphate and glucuronide conjugates of deuterated α -HTBZ and deuterated β -HTBZ, as well as products of oxidative metabolism, accounted for the majority of metabolites in the urine.

Based on population pharmacokinetic modelling, after oral administration, for deutetrabenazine, deuterated α -HTBZ and deuterated β -HTBZ, the apparent clearance values (CL/F) are 11,750 L/h, 67 L/h, and 260 L/h; the half-lives are 11.4 h, 11 h, and 8.2 h.

Deutetrabenazine and its active metabolites are not substrates or inhibitors of the human transporters, predominantly located in the liver, intestines, central nervous system (CNS) and kidney, that were studied *in vitro* at clinically relevant concentrations.

Linearity/non-linearity

Dose proportionality was observed in the dose range of 12 mg to 48 mg.

Special populations

Based on population pharmacokinetic analyses there is no apparent effect of gender, race, and age (18-64 years) on the pharmacokinetics of deuterated α -HTBZ and deuterated β -HTBZ.

Limited pharmacokinetic data are available for patients 65-74 years of age (approx. 9% of the patients) and 75-84 years of age (approx. 1% of the patients). No data are available for those over 85 years of age. Therefore, no definitive pharmacokinetic conclusions can be made for patients over 65 years of age.

The majority of patients had a body weight of 50 kg to <120 kg, and only a limited number of patients with a body weight of <50 kg or \geq 120 kg were included in clinical trials. Population pharmacokinetic analyses predict higher exposures of deuterated α -HTBZ and deuterated β -HTBZ in patients with lower body weights and lower exposures in patients with higher body weights, however, body weight was not correlated to individual response as measured by change in AIMS total score at week 12 of treatment.

Renal impairment

No clinical studies have been conducted to assess the effect of renal impairment on the pharmacokinetics of deuterated α -HTBZ and deuterated β -HTBZ. Based on population pharmacokinetic analyses, the effect of renal impairment on the pharmacokinetic exposures of deuterated total ($\alpha+\beta$)-HTBZ is negligible. As the major route of elimination of the active metabolites is non-renal, it is unlikely that patients with any degree of renal impairment will be exposed to excessive concentrations of deutetrabenazine and its active metabolites.

Hepatic impairment

The effect of hepatic impairment on the pharmacokinetics of deutetrabenazine and its active metabolites has not been studied. Since deutetrabenazine is extensively metabolised in the liver and due to the potential increase in systemic exposure the use of deutetrabenazine in patients with hepatic impairment is contraindicated (see section 4.3).

Poor CYP2D6 metabolisers

Although the pharmacokinetics of deutetrabenazine and its metabolites have not been systematically evaluated in patients who do not express the drug-metabolising enzyme CYP2D6, data in healthy subjects who are poor CYP2D6 metabolisers shows that the exposure to deuterated α -HTBZ and deuterated β -HTBZ would be increased similarly to taking strong CYP2D6 inhibitors (maximum exposure increased 2-fold and total exposure approximately 4-fold) (see sections 4.2 and 4.5).

5.3 Preclinical safety data

After 4 weeks of dosing (interim necropsy) in a 3-month toxicology study of deutetrabenazine in rats, observations of oestrus cycle arrest at the pro-oestrus (pre-ovulatory) phase and mammary hyperplasia in females at exposures similar to those expected in patients were likely physiological consequences of reduced CNS dopamine with attendant disinhibition of prolactin. CNS-related observations in this study, including intermittent tremors, partial eye closure, changes in activity, and twitching ears, that were observed at clinically relevant doses, with subclinical exposure to some major metabolites, were likely associated with depletion of monoamine neurotransmitter stores. Male rats from the 3-month study, at deutetrabenazine exposures slightly below clinical exposure levels, showed adverse effect of decreased body weight gains.

Non-rodent toxicology studies of deutetrabenazine were not conducted. However, observations in a toxicology study of another VMAT2 inhibitor (tetrabenazine) that was orally administered to dogs for 9 months revealed CNS-related pharmacological effects similar to rats, including hypoactivity, lethargy, strabismus, or closed eyes at doses associated with major human metabolite exposures below clinical exposure levels.

Deutetrabenazine and its major active metabolites, deuterated α -HTBZ and deuterated β -HTBZ, were not genotoxic in a standard battery of *in vitro* assays, and deutetrabenazine treatment resulted in a negative response for the induction of bone marrow micronuclei in mice.

Carcinogenicity studies of deutetrabenazine were not conducted.

Deutetrabenazine had no effect on embryofoetal development when administered to pregnant rats at doses up to 30 mg/kg/day corresponding to exposure levels (AUC) 119-fold higher than in patients at the maximum recommended dose. Exposure levels (AUC) to deuterated α -HTBZ were comparable and deuterated β -HTBZ metabolites were slightly lower than the metabolite levels in humans at the maximum recommended dose.

No embryofoetal development studies in a non-rodent species, or fertility and pre- and post-natal development studies in a rodent species were conducted with deutetrabenazine.

Tetrabenazine had no effects on embryofoetal development when administered to pregnant rabbits during the period of organogenesis at oral doses up to 60 mg/kg/day.

When tetrabenazine was orally administered to pregnant rats (5, 15, and 30 mg/kg/day) from the beginning of organogenesis through the lactation period, an increase in stillbirths and offspring postnatal mortality was observed at 15 and 30 mg/kg/day and delayed pup maturation was observed at all doses. A no-effect dose for pre- and postnatal developmental toxicity in rats was not identified.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

Butylhydroxyanisole (E 320)
Butylhydroxytoluene (E 321)
Macrogol high-molecular-mass 200K
Macrogol high-molecular-mass 5000K
Hypromellose 2910
Sodium chloride
Allura red AC (E 129)
Magnesium stearate
Cellulose acetate
Macrogol 3350
Hydroxypropylcellulose

Film-coating

Poly(vinyl alcohol)
Titanium dioxide (E 171)
Macrogol 3350
Talc
Austedo 12 mg
Indigo carmine (E 132)
Austedo 24 mg
Indigo carmine (E 132)
Allura red AC (E 129)
Austedo 30 mg
Sunset yellow FCF (E 110)

Austedo 36 mg
Indigo carmine (E 132)
Sunset yellow FCF (E 110)
Allura red AC (E 129)
Austedo 42 mg
Sunset yellow FCF (E 110)
Allura red AC (E 129)
Austedo 48 mg
Allura red AC (E 129)

Printing ink

Shellac
Iron oxide black (E 172)
Propylene glycol

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (treatment initiation pack)
2 years

Austedo 24 mg prolonged-release tablets (maintenance pack)
3 years

Austedo 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (maintenance packs)
2 years

6.4 Special precautions for storage

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (treatment initiation pack)
Do not store above 30 °C.

Austedo 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (maintenance packs)
This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PCTFE/PVC-Aluminium blisters

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (treatment initiation pack)
Pack of 42 prolonged-release tablets containing two wallet cards one with 21 (7 × 12 mg, 7 × 24 mg, 7 × 30 mg) and another one with 21 (7 × 36 mg, 7 × 42 mg, 7 × 48 mg) prolonged-release tablets.

Austedo 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (maintenance packs)
Packs of 28 and 84 prolonged-release tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

8. MARKETING AUTHORISATION NUMBER(S)

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (treatment initiation pack)

EU/1/25/1956/001

Austedo 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (maintenance packs)

EU/1/25/1956/002 - 24 mg (28 prolonged-release tablets)
EU/1/25/1956/003 - 24 mg (84 prolonged-release tablets)
EU/1/25/1956/004 - 30 mg (28 prolonged-release tablets)
EU/1/25/1956/005 - 30 mg (84 prolonged-release tablets)
EU/1/25/1956/006 - 36 mg (28 prolonged-release tablets)
EU/1/25/1956/007 - 36 mg (84 prolonged-release tablets)
EU/1/25/1956/008 - 42 mg (28 prolonged-release tablets)
EU/1/25/1956/009 - 42 mg (84 prolonged-release tablets)
EU/1/25/1956/010 - 48 mg (28 prolonged-release tablets)
EU/1/25/1956/011 - 48 mg (84 prolonged-release tablets)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

ANNEX II

- A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Teva Operations Poland Sp. z o.o.
ul. Mogilska 80,
Kraków, 31-546
Poland

Teva Czech Industries s.r.o.
Ostravská 29, c.p. 305
747 70 Opava-Komárov
Czech Republic

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON for treatment initiation pack (42 tablets, week 1-6), containing two wallet cards

1. NAME OF THE MEDICINAL PRODUCT

Austedo 12 mg prolonged-release tablets
Austedo 24 mg prolonged-release tablets
Austedo 30 mg prolonged-release tablets
Austedo 36 mg prolonged-release tablets
Austedo 42 mg prolonged-release tablets
Austedo 48 mg prolonged-release tablets
deutetetabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 12 mg, 24 mg, 30 mg, 36 mg, 42 mg or 48 mg of deutetetabenazine.

3. LIST OF EXCIPIENTS

Austedo 12 mg/24 mg/48 mg contains allura red AC (E 129). Austedo 30 mg/36 mg/42 mg contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

Treatment initiation pack

42 prolonged-release tablets

Each pack of 42 prolonged-release tablets contains two wallet cards, one with 21 (7 x 12 mg, 7 x 24 mg, 7 x 30 mg) and another one with 21 (7 x 36 mg, 7 x 42 mg, 7 x 48 mg) prolonged-release tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**WALLET CARD for treatment initiation pack (21 tablets, week 1-3)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 12 mg prolonged-release tablets

Austedo 24 mg prolonged-release tablets

Austedo 30 mg prolonged-release tablets

deutetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 12 mg, 24 mg or 30 mg of deutetrabenazine.

3. LIST OF EXCIPIENTS

Austedo 12 mg/24 mg contains allura red AC (E 129). Austedo 30 mg contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

21 (7 x 12 mg, 7 x 24 mg, 7 x 30 mg) prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

Week 1, Week 2, Week 3

Week 1	Week 2	Week 3
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg
12 mg	24 mg	30 mg

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Austedo 12 mg, 24 mg, 30 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER for treatment initiation pack (21 tablets, week 1-3), inside the wallet card

1. NAME OF THE MEDICINAL PRODUCT

Austedo 12 mg

Austedo 24 mg

Austedo 30 mg

deutetrabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**WALLET CARD for treatment initiation pack (21 tablets, week 4-6)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 36 mg prolonged-release tablets

Austedo 42 mg prolonged-release tablets

Austedo 48 mg prolonged-release tablets

deutetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 36 mg, 42 mg or 48 mg of deutetrabenazine.

3. LIST OF EXCIPIENTS

Austedo 48 mg contains allura red AC (E 129). Austedo 36 mg/42 mg contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

21 (7 x 36 mg, 7 x 42 mg, 7 x 48 mg) prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

Week 4, Week 5, Week 6

Week 4	Week 5	Week 6
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg
36 mg	42 mg	48 mg

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE****11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Austedo 36 mg, 42 mg, 48 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER for treatment initiation pack (21 tablets, week 4-6), inside the wallet card

1. NAME OF THE MEDICINAL PRODUCT

Austedo 36 mg

Austedo 42 mg

Austedo 48 mg

deutetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**CARTON (maintenance pack)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 24 mg prolonged-release tablets
deutetetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 24 mg of deutetetrabenazine.

3. LIST OF EXCIPIENTS

Contains allura red AC (E 129). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

28 prolonged-release tablets
84 prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/002 - 28 prolonged-release tablets
EU/1/25/1956/003 - 84 prolonged-release tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Austedo 24 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER (maintenance pack)

1. NAME OF THE MEDICINAL PRODUCT

Austedo 24 mg prolonged-release tablets
deutetetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**CARTON (maintenance pack)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 30 mg prolonged-release tablets
deutetetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 30 mg of deutetetrabenazine.

3. LIST OF EXCIPIENTS

Contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

28 prolonged-release tablets
84 prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/004 - 28 prolonged-release tablets
EU/1/25/1956/005 - 84 prolonged-release tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Austedo 30 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER (maintenance pack)

1. NAME OF THE MEDICINAL PRODUCT

Austedo 30 mg prolonged-release tablets
deutetetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**CARTON (maintenance pack)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 36 mg prolonged-release tablets
deutetetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 36 mg of deutetetrabenazine.

3. LIST OF EXCIPIENTS

Contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

28 prolonged-release tablets
84 prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/006 - 28 prolonged-release tablets
EU/1/25/1956/007 - 84 prolonged-release tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Austedo 36 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER (maintenance pack)

1. NAME OF THE MEDICINAL PRODUCT

Austedo 36 mg prolonged-release tablets
deutetetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**CARTON (maintenance pack)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 42 mg prolonged-release tablets
deutetetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 42 mg of deutetetrabenazine.

3. LIST OF EXCIPIENTS

Contains allura red AC (E 129) and sunset yellow FCF (E 110). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

28 prolonged-release tablets
84 prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/008 - 28 prolonged-release tablets
EU/1/25/1956/009 - 84 prolonged-release tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Austedo 42 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER (maintenance pack)

1. NAME OF THE MEDICINAL PRODUCT

Austedo 42 mg prolonged-release tablets
deutetetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**CARTON (maintenance pack)****1. NAME OF THE MEDICINAL PRODUCT**

Austedo 48 mg prolonged-release tablets
deutetetrabenazine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each prolonged-release tablet contains 48 mg of deutetetrabenazine.

3. LIST OF EXCIPIENTS

Contains allura red AC (E 129). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Prolonged-release tablet

28 prolonged-release tablets
84 prolonged-release tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

Swallow whole, do not chew, crush or divide.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/25/1956/010 - 28 prolonged-release tablets
EU/1/25/1956/011 - 84 prolonged-release tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Austedo 48 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER (maintenance pack)

1. NAME OF THE MEDICINAL PRODUCT

Austedo 48 mg prolonged-release tablets
deutetetabenazine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Austedo 12 mg prolonged-release tablets
Austedo 24 mg prolonged-release tablets
Austedo 30 mg prolonged-release tablets
Austedo 36 mg prolonged-release tablets
Austedo 42 mg prolonged-release tablets
Austedo 48 mg prolonged-release tablets
deutetrabenazine

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Austedo is and what it is used for
2. What you need to know before you take Austedo
3. How to take Austedo
4. Possible side effects
5. How to store Austedo
6. Contents of the pack and other information

1. What Austedo is and what it is used for

Austedo is a medicine containing the active substance deutetrabenazine. It belongs to a group of medicines that treat disorders of the nervous system.

This medicine is used in adults to treat moderate to severe tardive dyskinesia. This is a condition that causes the face, tongue, or other body parts to make uncontrollable movements such as smacking of the lips, sticking out of the tongue and jerking or twisting of the arms and legs, and can develop with use of certain medicines.

Austedo decreases the uncontrollable movements associated with tardive dyskinesia by reducing the amount of dopamine, a messenger substance in the brain.

2. What you need to know before you take Austedo

Do not take Austedo

- if you are allergic to deutetrabenazine or any of the other ingredients of this medicine (listed in section 6).
- if you have liver problems.
- if you are taking
 - reserpine (a medicine used to treat high blood pressure)
 - a monoamine oxidase inhibitor (a medicine used to treat depression, Parkinson's disease or bacterial infections)
 - another medicine that works in a similar way to Austedo to reduce your uncontrollable movements.

(see "Other medicines and Austedo", in this section).

If you are not sure, talk to your doctor or pharmacist before taking this medicine.

Warnings and precautions

Talk to your doctor or pharmacist **before** taking Austedo

- if you have or have had depression
- if you have or have had an irregular heart rhythm
- if you have a family history of a heart condition known as congenital long QT syndrome (abnormal electrical activity of the heart that affects its rhythm)
- if you have a slow heart rate
- if you have low levels of potassium or magnesium, as seen in your blood tests.

Talk to your doctor immediately **while** taking Austedo

- if you start feeling sad, worthless, hopeless or helpless or start losing interest in seeing your friends or doing things you used to enjoy (symptoms of a depression). If these symptoms do not get better, your doctor might consider stopping Austedo. You may find it helpful to ask a relative or close friend to tell your doctor immediately if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.
- if you start experiencing a rapid onset of shortness of breath, heart palpitations (sensation of rapid or irregular heartbeat) or loss of consciousness. These may be symptoms of a heart rhythm disorder known as QTc prolongation.
- if you start experiencing symptoms like high temperature, muscle stiffness, sweating, a lowered level of consciousness or very rapid or irregular heartbeat, low or high blood pressure. This is known as neuroleptic malignant syndrome, which can be life-threatening. Stop taking Austedo and talk to your doctor straight away. Your doctor will treat your symptoms.
- if you get a condition where you feel a constant urge to move (akathisia) or if you experience shaking, muscle stiffness and slow movement (parkinsonism). Your doctor may need to adjust your dose or stop your treatment.

Talk to your doctor if you notice new skin or eye problems. Deutetrabenazine binds to body tissues that contain melanin (a pigment that gives colour to skin and eyes). This may possibly affect these tissues if the medicine is used long-term.

Children and adolescents

There is no relevant use of Austedo in children and adolescents.

Other medicines and Austedo

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take this medicine if you are already taking

- reserpine (a medicine used to treat high blood pressure). After your doctor has stopped reserpine you must wait at least 20 days after your last dose of reserpine before you can start taking Austedo.
- a monoamine oxidase inhibitor (MAOI), e.g.
 - moclobemide, tranylcypromine and isocarboxazid (medicines used to treat depression)
 - selegiline, rasagiline and safinamide (medicines used to treat Parkinson's disease)
 - linezolid (medicine used to treat bacterial infections).

After your doctor has stopped the MAOI you must wait at least 14 days after your last dose of the MAOI before you can start taking Austedo.

- another medicine that works in a similar way to Austedo to reduce your uncontrollable movements (e.g. tetrabenazine). Your doctor will decide and tell you what to do.

Tell your doctor if you are taking, have recently taken or might take

- medicines to treat
 - some mental or behavioural problems (e.g. psychosis, such as haloperidol, chlorpromazine, ziprasidone, promazine)

- nausea and vomiting (e.g. metoclopramide)

These medicines may increase the risk for symptoms such as shaking, muscle stiffness and slow movement (called parkinsonism), high temperature, muscle stiffness, low or high blood pressure and lowered level of consciousness (called neuroleptic malignant syndrome), or a constant urge to move (called akathisia).

- medicines that can influence your heart rhythm (visible on electrocardiogram) also known as QTc prolongation, for example, medicines used to treat
 - an irregular heart rhythm (e.g. quinidine, disopyramide, amiodarone, sotalol)
 - some mental or behavioural problems (e.g. phenothiazine derivatives, pimozide, haloperidol, droperidol, ziprasidone)
 - depression (e.g. amitriptyline, citalopram, escitalopram)
 - bacterial, fungal or other microbial infections (e.g. fluoroquinolones, triazole derivative (e.g. voriconazole), erythromycin IV, pentamidine, antimalarial medicines)
 - allergies (e.g. mizolastine, hydroxyzine)
- medicines that have a sedating effect, for example, medicines
 - to treat allergic conditions (e.g. diphenhydramine, dimenhydrinate)
 - to help you sleep or to calm down (e.g. midazolam, diazepam, lorazepam)
 - to treat severe pain (e.g. oxycodone, buprenorphine)
 - to treat high blood pressure (e.g. clonidine, moxonidine)
 - to treat depression (e.g. mirtazapine, amitriptyline, trazodone)
 - to treat some mental or behavioural problems (e.g. promethazine, chlorprothixene)

These medicines may increase the sedation and sleepiness which could be caused by Austedo.

- medicines to treat an irregular heart rhythm (e.g. quinidine) or depression (e.g. paroxetine, fluoxetine and bupropion). These medicines can interfere with the breakdown of deutetrabenazine. Your doctor may decrease your dose of Austedo.
- medicines to treat Parkinson's disease (e.g. levodopa) and medicines that work in a similar way like levodopa (e.g. also to treat Parkinson's disease and restless legs syndrome, e.g. pramipexole, ropinirole). These medicines may weaken the effect of Austedo.

Austedo with alcohol

It is not recommended to consume alcohol while you are being treated with Austedo, as it may increase the sedative effect and sleepiness that could be caused by this medicine.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Austedo is not recommended during pregnancy and in women of childbearing potential not using contraception.

It is not known if deutetrabenazine passes into breast milk. Thus, a risk for the breast-fed baby cannot be excluded. You should discuss with your doctor if you can take Austedo while breast-feeding.

Driving and using machines

Austedo may cause sleepiness. Therefore, you should not perform activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery, until you are on your maintenance dose of Austedo and you know how the medicine affects you.

Austedo contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release tablet, that is to say essentially 'sodium-free'.

Austedo contains sunset yellow FCF and/or allura red AC (see section 6 "What Austedo contains")

This medicine may cause allergic reactions.

3. How to take Austedo

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Your doctor will decide what dose is appropriate for you.

When you first start taking Austedo, you will be given a treatment initiation pack which your doctor will use to gradually increase your dose. Treatment starts at 12 mg once daily for one week. After that, the dose should be increased to 24 mg once daily for another week. Then, the dose can be adjusted weekly if needed, increasing by 6 mg each time, until you have reached a dose that effectively controls your symptoms and is well-tolerated. This becomes your maintenance dose (usually between 24 mg and 48 mg per day).

Consult your doctor if your symptoms worsen or side effects occur.

The prolonged-release tablets are for oral use and can be taken with or without food.

Tablets must be swallowed whole with water, not chewed, crushed or divided.

The tablet does not dissolve completely after all of the active substance has been released and sometimes the tablet shell may appear in your stool. This is normal.

If you take more Austedo than you should

If you have taken more tablets than prescribed contact your doctor or nearest hospital straight away. You may experience symptoms such as sleepiness, increase in movements, tiredness, difficulty sitting and standing still (agitation), restlessness, difficulty falling and staying asleep, or suicidal thoughts or ideas.

If you forget to take Austedo

If you have missed your daily dose for one day or several days in a row (but not for more than 7 days), continue taking your current dose the next day. Contact your doctor if there are any concerns or you are unsure what to do. Do not take a double dose to make up for a missed dose.

If you have missed your daily dose for more than one week ask your doctor how your treatment should be restarted.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Please contact your doctor immediately if you start feeling sad, worthless, hopeless or helpless or start losing interest in seeing your friends or doing things you used to enjoy. These are symptoms of a depression or dysthymic disorder, which may occur commonly (may affect up to 1 in 10 people).

Very common (may affect more than 1 in 10 people)

- Sleepiness (somnolence)

Common (may affect up to 1 in 10 people)

- Infection of the parts of the body that collect and pass out urine, such as the bladder (urinary tract infection)
- Inflammation of the nose and throat (nasopharyngitis)
- Feeling anxious
- Difficulty sleeping (insomnia)
- Difficulty standing or sitting still (agitation)
- Restlessness
- A constant urge to move (akathisia)
- Diarrhoea

- Constipation
- Dry mouth
- Tiredness (fatigue)
- Bruising (contusion)

Uncommon (may affect up to 1 in 100 people)

- Movement symptoms similar to Parkinson's disease such as shaking, muscle stiffness and slow movement (parkinsonism)

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Austedo

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg prolonged-release tablets (treatment initiation pack)

Do not store above 30 °C.

Austedo 24 mg, 30 mg, 36 mg, 42 mg and 48 mg prolonged-release tablets (maintenance packs)

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Austedo contains

- The active substance is deutetetrabenazine.
Each prolonged release tablet contains either 12 mg, 24 mg, 30 mg, 36 mg, 42 mg or 48 mg deutetetrabenazine.
- The other ingredients are
 - Tablet: butylhydroxyanisole (E 320), butylhydroxytoluene (E 321), macrogol high-molecular-mass 200K, macrogol high-molecular-mass 5000K, hypromellose 2910, sodium chloride, allura red AC (E 129), magnesium stearate, cellulose acetate, macrogol 3350, hydroxypropylcellulose.
 - Film-coating: poly(vinyl alcohol), titanium dioxide (E 171), macrogol 3350, talc
 - Austedo 12 mg:* indigo carmine (E 132)
 - Austedo 24 mg:* indigo carmine (E 132), allura red AC (E 129)
 - Austedo 30 mg:* sunset yellow FCF (E 110)
 - Austedo 36 mg:* indigo carmine (E 132), sunset yellow FCF (E 110), allura red AC (E 129)
 - Austedo 42 mg:* sunset yellow FCF (E 110), allura red AC (E 129)
 - Austedo 48 mg:* allura red AC (E 129).
 - See section 2 "Austedo contains sunset yellow FCF and/or allura red AC".
- Printing ink: shellac, iron oxide black (E 172), propylene glycol.

What Austedo looks like and contents of the pack

Austedo 12 mg prolonged-release tablets are round, blue, film-coated, with a diameter of approximately 9 mm and "Q12" printed in black ink on one side.

Austedo 24 mg prolonged-release tablets are round, purple, film-coated, with a diameter of approximately 9 mm and "Q24" printed in black ink on one side.

Austedo 30 mg prolonged-release tablets are round, light orange, film-coated, with a diameter of approximately 10 mm and "Q30" printed in black ink on one side.

Austedo 36 mg prolonged-release tablets are round, light purple, film-coated, with a diameter of approximately 10 mm and "Q36" printed in black ink on one side.

Austedo 42 mg prolonged-release tablets are round, orange, film-coated, with a diameter of approximately 10 mm and "Q42" printed in black ink on one side.

Austedo 48 mg prolonged-release tablets are round, pink, film-coated, with a diameter of approximately 10 mm and "Q48" printed in black ink on one side.

Treatment initiation pack

Austedo 12 mg, 24 mg, 30 mg, 36 mg, 42 mg, 48 mg is available in a pack of 42 prolonged-release tablets containing two wallet cards one with 21 (7 x 12 mg, 7 x 24 mg, 7 x 30 mg) and another one with 21 (7 x 36 mg, 7 x 42 mg, 7 x 48 mg) prolonged-release tablets.

Maintenance packs

Austedo 24 mg, 30 mg, 36 mg, 42 mg, 48 mg are available in packs of 28 and 84 prolonged-release tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany

Manufacturer

Teva Operations Poland Sp. z o.o.
ul. Mogilska 80,
Kraków, 31-546
Poland

Teva Czech Industries s.r.o.
Ostravská 29, c.p. 305
747 70 Opava-Komárov
Czech Republic

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Teva Pharma Belgium N.V./S.A./AG
Tél/Tel: +32 38207373

България

Тева Фарма ЕАД
Тел.: +359 24899585

Lietuva

UAB Teva Baltics
Tel: +370 52660203

Luxembourg/Luxemburg

Teva Pharma Belgium N.V./S.A./AG
Belgique/Belgien
Tél/Tel: +32 38207373

Česká republika
Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251007111

Danmark
Teva Denmark A/S
Tlf.: +45 44985511

Deutschland
TEVA GmbH
Tel: +49 73140208

Eesti
UAB Teva Baltics Eesti filiaal
Tel: +372 6610801

Ελλάδα
TEVA HELLAS A.E.
Τηλ: +30 2118805000

España
Teva Pharma, S.L.U.
Tel: +34 915359180

France
Teva Santé
Tél: +33 155917800

Hrvatska
Pliva Hrvatska d.o.o.
Tel: +385 13720000

Ireland
Teva Pharmaceuticals Ireland
Tel: +44 2075407117

Ísland
Teva Pharma Iceland ehf.
Sími: +354 5503300

Italia
Teva Italia S.r.l.
Tel: +39 028917981

Κύπρος
TEVA HELLAS A.E.
Ελλάδα
Τηλ: +30 2118805000

Latvija
UAB Teva Baltics filiāle Latvijā
Tel: +371 67323666

Magyarország
Teva Gyógyszergyár Zrt.
Tel.: +36 12886400

Malta
TEVA HELLAS A.E.
il-Greċċa
Tel: +356 2118805000

Nederland
Teva Nederland B.V.
Tel: +31 8000228400

Norge
Teva Norway AS
Tlf: +47 66775590

Österreich
ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43 1970070

Polska
Teva Pharmaceuticals Polska Sp. z o.o.
Tel.: +48 223459300

Portugal
Teva Pharma - Produtos Farmacêuticos, Lda.
Tel: +351 214767550

România
Teva Pharmaceuticals S.R.L.
Tel: +40 212306524

Slovenija
Pliva Ljubljana d.o.o.
Tel: +386 15890390

Slovenská republika
TEVA Pharmaceuticals Slovakia s.r.o.
Tel: +421 257267911

Suomi/Finland
Teva Finland Oy
Puh/Tel: +358 201805900

Sverige
Teva Sweden AB
Tel: +46 42121100

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

<https://www.ema.europa.eu>.